We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+15.92%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$384M
AUM Growth
+$106M
(+38%)
Cap. Flow
+$68.6M
Cap. Flow
% of AUM
17.89%
Top 10 Holdings %
Top 10 Hldgs %
38.06%
Holding
80
New
28
Increased
20
Reduced
13
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$13.1M |
| 2 |
CVS Health
CVS
|
+$12.2M |
| 3 |
Iovance Biotherapeutics
IOVA
|
+$10.6M |
| 4 |
IVC
Invacare Corporation
IVC
|
+$10.3M |
| 5 |
OrthoPediatrics
KIDS
|
+$9.75M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
+$39.1M |
| 2 |
Aclaris Therapeutics
ACRS
|
+$13.1M |
| 3 |
SI-BONE Inc
SIBN
|
+$7.62M |
| 4 |
Smith & Nephew
SNN
|
+$7.55M |
| 5 |
Cigna
CI
|
+$5.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.29% |
| 2 | Miscellaneous | 9.01% |
| 3 | Industrials | 0.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
OrthoPediatrics
KIDS
$604M
| $19.3M | 5.04% |
396,162
+203,154
| +105% | +$9.75M |
|
2
CALL
Actinium Pharmaceuticals
ATNM
$39M
| $15.2M | 3.97% |
+2,000,000
| New | +$17M |
|
3
Bristol-Myers Squibb
BMY
$130B
| $14.8M | 3.85% |
233,898
-10,168
| -4% | -$633K |
|
4
AdaptHealth
AHCO
$788M
| $14.7M | 3.83% |
399,730
+249,316
| +166% | +$8.81M |
|
|
5
Sanofi
SNY
$102B
| $13.5M | 3.51% |
+272,218
| New | +$13.1M |
|
6
Becton Dickinson
BDX
$49.5B
| $13.2M | 3.45% |
55,714
-15,282
| -22% | -$3.73M |
|
|
7
CVS Health
CVS
$117B
| $12.6M | 3.28% |
+167,362
| New | +$12.2M |
|
8
AstraZeneca
AZN
$253B
| $11.8M | 3.09% |
119,050
+90,604
| +319% | +$9.11M |
|
9
Labcorp
LH
$26.3B
| $11.5M | 3.01% |
52,641
+29,554
| +128% | +$5.93M |
|
|
10
Aclaris Therapeutics
ACRS
$783M
| $11.5M | 2.99% |
455,385
-671,290
| -60% | -$13.1M |
|
11
Elevance Health
ELV
$89.5B
| $11.4M | 2.98% |
31,798
+9,164
| +40% | +$2.95M |
|
12
Encompass Health
EHC
$12.2B
| $11M | 2.86% |
168,188
+76,296
| +83% | +$4.98M |
|
|
13
Iovance Biotherapeutics
IOVA
$4.47B
| $9.84M | 2.56% |
310,649
+256,428
| +473% | +$10.6M |
|
14
AbbVie
ABBV
$464B
| $9.52M | 2.48% |
87,982
+3,438
| +4% | +$368K |
|
|
MTEM
15
DELISTED
Molecular Templates, Inc.
MTEM
| $8.95M | 2.33% |
47,291
+1,875
| +4% | +$329K |
|
|
IVC
16
DELISTED
Invacare Corporation
IVC
| $8.88M | 2.32% |
+1,107,112
| New | +$10.3M |
|
17
McKesson
MCK
$103B
| $8.61M | 2.24% |
+44,132
| New | +$8.06M |
|
18
Bio-Rad Laboratories Class A
BIO
$10.1B
| $8.44M | 2.2% |
+14,784
| New | +$8.75M |
|
19
Elutia
ELUT
$35.9M
| $8.06M | 2.1% |
583,600
+175,387
| +43% | +$2.62M |
|
|
SYNH
20
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $8M | 2.09% |
105,521
+3,568
| +3% | +$269K |
|
|
PHAS
21
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $7.49M | 1.95% |
+2,163,518
| New | +$8.78M |
|
22
Cencora
COR
$60.8B
| $7.41M | 1.93% |
62,722
-15,617
| -20% | -$1.69M |
|
23
Ocular Therapeutix
OCUL
$2.17B
| $7.2M | 1.88% |
438,933
+148,468
| +51% | +$2.86M |
|
24
Avantor
AVTR
$10.6B
| $6.97M | 1.82% |
241,016
+46,239
| +24% | +$1.33M |
|
25
Boston Scientific
BSX
$63.6B
| $6.13M | 1.6% |
+158,702
| New | +$6.01M |
|
Similar funds
UVM
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
Endurant Capital Management's Q1 2021 Portfolio in Review
As of Q1 2021, Endurant Capital Management held 80 positions worth $384M, up 38% from $277M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Endurant Capital Management deployed $68.6M of net new capital in Q1 2021, opening 28 new positions and adding to 20 existing holdings. Its largest new stake was Sanofi: 272,218 shares worth $13.5M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $13.1M trimmed.
- Endurant Capital Management's largest Q1 2021 buy was Sanofi: 272,218 shares worth $13.5M.
- Endurant Capital Management added most to Iovance Biotherapeutics in Q1 2021, an estimated $10.6M increase.
- Endurant Capital Management's biggest Q1 2021 reduction was Aclaris Therapeutics, cutting an estimated $13.1M.
- Endurant Capital Management fully exited Oxford Immunotec Global PLC Ordinary Shares in Q1 2021, selling an estimated $39.1M.
- Endurant Capital Management's ten largest holdings make up 38% of its $384M portfolio in Q1 2021.
- Endurant Capital Management opened 28 new positions and closed 19 in Q1 2021.
- Endurant Capital Management's portfolio value rose 38% quarter-over-quarter to $384M.
Based on Endurant Capital Management's 13F filing for Q1 2021, filed 17 May 2021.